Yat Sun Or - Feb 13, 2023 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & CSO
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Feb 13, 2023
Transactions value $
-$409,073
Form type
4
Date filed
2/15/2023, 08:46 PM
Previous filing
Dec 5, 2022
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Award $0 +10.3K +2.85% $0.00 369K Feb 13, 2023 Direct F1
transaction ENTA Common Stock Award $0 +13K +3.52% $0.00 382K Feb 13, 2023 Direct F2
transaction ENTA Common Stock Tax liability -$409K -7.75K -2.03% $52.77 375K Feb 13, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 18, 2020 that vested as a result of the achievement of a research and development milestone in calendar 2022 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 13, 2023.
F2 Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 18, 2020 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 13, 2023.
F3 Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.